Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress towards a new tuberculosis vaccine.

D B Lowrie1, C L Silva, R E Tascon

  • 1National Institute for Medical Research, London, England. d-lowrie@nimr.mrc.ac.uk

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Centrality-Dependent Modification of Jet-Production Rates in Deuteron-Gold Collisions at sqrt[s_{NN}]=200  GeV [Phys. Rev. Lett. 116, 122301 (2016)].

Physical review letters·2025
Same author

Disentangling Centrality Bias and Final-State Effects in the Production of High-p_{T} Neutral Pions Using Direct Photon in d+Au Collisions at sqrt[s_{NN}]=200  GeV.

Physical review letters·2025
Same author

On the origin of low-valent uranium oxidation state.

Nature communications·2024
Same author

Measurement of Direct-Photon Cross Section and Double-Helicity Asymmetry at sqrt[s]=510  GeV in p[over →]+p[over →] Collisions.

Physical review letters·2023
Same author

Accumulation and decomposition of cultural residues of Theobroma grandiflorum, Paullinia cupana, Bixa orellana and forest in the southern region of Amazonas.

Brazilian journal of biology = Revista brasleira de biologia·2023
Same author

Probing Gluon Spin-Momentum Correlations in Transversely Polarized Protons through Midrapidity Isolated Direct Photons in p^{↑}+p Collisions at sqrt[s]=200  GeV.

Physical review letters·2021
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Developing a new tuberculosis vaccine is a simpler goal than new drugs due to resistance concerns. Research shows protein antigens administered via DNA vaccines can induce protective immunity against tuberculosis.

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • Tuberculosis (TB) requires new treatments, including drugs and vaccines, to combat drug resistance.
  • Developing new anti-TB drugs is challenging due to emerging resistance, necessitating combination therapies.
  • An effective TB vaccine offers a promising alternative, potentially overcoming resistance issues with multiple antigenic targets.

Purpose of the Study:

  • To explore the potential of novel vaccine strategies against tuberculosis.
  • To identify protective antigens and evaluate vaccine delivery methods for inducing cell-mediated immunity.

Main Methods:

  • Investigated protein antigens administered with adjuvants or as DNA vaccines in animal models.
  • Assessed protective immunity by measuring accelerated bacterial multiplication arrest and sustained decline.

Related Experiment Videos

  • Utilized adoptive transfer of T cells to demonstrate the role of cytotoxic T cells in protection.

    • Main Results:

    • Diverse protein antigens, including secreted and stress proteins (e.g., Ag85, ESAT-6), induced high levels of protective immunity in animal models.
    • Protection involved antigen-specific cytotoxic T cells producing interferon-gamma and lysing infected macrophages.
    • DNA vaccination demonstrated superiority over recombinant vectors for inducing protective immunity.

    Conclusions:

    • Novel TB vaccines targeting diverse antigens, particularly through DNA vaccination, show significant promise.
    • Cell-mediated immunity, driven by cytotoxic T cells, is crucial for protection against tuberculosis.
    • Further research into TB vaccine development is warranted, focusing on antigens produced by actively multiplying and growth-inhibited bacteria.